search
Back to results

Oral Nutritional Supplement on Nutritional and Functional Status, and Biomarkers in Malnourished Hemodialysis Patients. (RENACARE)

Primary Purpose

Malnutrition, End Stage Renal Disease

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Oral nutritional supplement with probiotics
Oral nutritional supplement without probiotics
Dietary recommendations
Sponsored by
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Malnutrition

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult subjects (>18 y/o) undergoing hemodialysis more than 6 months previous at inclusion.
  • At least one of these caloric malnutrition criteria: a) involuntary weight loss >5% in 3 months or >10% in 6 months; b) serum albumin < 3.5 g/dl or prealbumin <28 mg/dl; c) body mass index (BMI) < 23 kg/m2; d) muscular mass loss >5% in 3 months or >10% in 6 months.
  • Standard hemodialysis therapy (3 days/week, 240 min, high permeability dialyzer, blood flow >250 ml/min and dialysate flow 500 ml/min) or on-line hemodialysis therapy that was not modified in the last 3 months previous to the inclusion.
  • Written informed consent obtained.

Exclusion Criteria:

  • Type 1 diabetes mellitus or type 2 diabetes mellitus with HbA1c>9%.
  • Unstable dry weight.
  • Limb amputation.
  • Significant edema.
  • Active malignancy.
  • Hospital admissions in the last 3 months.
  • Acute gastrointestinal disease in the 2 weeks before the inclusion.
  • Gastrectomy, gastroparesis or abnormal gastric emptying.
  • Acute heart failure grade IV.
  • Severe hepatic insufficiency (men gamma glutamyl transferase -GGT- >150 U/l, women >120 U/l).
  • Alcohol or other drugs abuse.
  • Participants enrolled in other research study at inclusion.
  • Pregnant women.
  • No informed consent obtained.
  • Patients who received any oral nutritional supplement (specific for hemodialysis patients or not) in the 4 weeks before the inclusion.
  • Patients receiving enteral tube feeding.
  • Galactosemia, fructosemia, or requirement of a no fiber diet.
  • Allergy or hypersensitivity to any ingredient of the oral nutritional supplement.
  • Ongoing treatment with glucocorticoids.
  • Patients who received any oral fatty acids omega-3 supplement in the 4 weeks before the inclusion.
  • Patients who received intradialytic parenteral nutrition in the 3 months before the inclusion.
  • Patients who received any probiotics or prebiotics (not as part of the diet) in the 3 months before the inclusion.
  • Anemia (Hemoglobin < 10 g/dl) or Epoetin resistance.

Sites / Locations

  • Hospital Universitario Rey Juan Carlos
  • Hospital San Cecilio
  • Hospital Regional Universitario de Málaga

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Oral nutritional supplement with probiotics

Oral nutritional supplement without probiotics

Individualized dietary recommendations

Arm Description

Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), with probiotics. Physical activity recommendations.

Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), without probiotics. Physical activity recommendations.

Individualized dietary recommendations. Physical activity recommendations.

Outcomes

Primary Outcome Measures

Change in weight
Weight in kg
Change in fat free body mass
Fat free body mass in kg assessed by bioelectrical impedance analysis
Change in serum albumin concentration
Serum albumin in g/dl
Change in serum prealbumin concentration
Serum prealbumin in mg/dl

Secondary Outcome Measures

Change in handgrip strength
Handgrip strength in kg, measured by the jamar hydraulic hand dynamometer.
Change in the score of the "Barthel" test.
The Barthel is a 10-item ordinal scale that measures functional independence in the domains of personal care and mobility. Specifically, it measures self-care, sphincter management, transfers and locomotion. The score ranges between 0 and 100 points. Scores of 0-20 indicate "total" dependency, 21-60 indicate "severe" dependency, 61-90 indicate "moderate" dependency, 91-99 indicates "slight" dependency, and 100 indicates independency.
Change in the score of the Hospital Anxiety and Depression Scale (HADS).
Symptoms of depression and anxiety assessed by the Hospital Anxiety and Depression Scale (HADS). This questionnaire comprises two sub-scales, each one range from 0 to 21 points; one assesses the symptoms of depression, and the other one the symptoms of anxiety. At each sub-scale, a score below 7 is considered normal range, between 8 and 10 means probable presence of depression or anxiety respectively, and more than 11 suggests the presence of depression or anxiety respectively.
Changes in plasma levels of high sensitivity C reactive protein (hs-CRP)
Plasma levels of high sensitivity C reactive protein (hs-CRP) in mg/dl
Changes in plasma levels of 8-iso-prostaglandina F2 α (8-iso-PGF2-α)
Plasma levels of 8-iso-prostaglandina F2 α (8-iso-PGF2-α) in pg/ml

Full Information

First Posted
April 8, 2019
Last Updated
June 22, 2021
Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
search

1. Study Identification

Unique Protocol Identification Number
NCT03924089
Brief Title
Oral Nutritional Supplement on Nutritional and Functional Status, and Biomarkers in Malnourished Hemodialysis Patients.
Acronym
RENACARE
Official Title
Effect of an Oral Nutritional Supplement on Nutritional and Functional Status, Biological Markers (Inflammation and Oxidative Stress, Intestinal Microbiota, Circulating microRNA and Its Target Genes) in Malnourished Hemodialysis Patients.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
April 15, 2019 (Actual)
Primary Completion Date
June 15, 2021 (Actual)
Study Completion Date
June 15, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Malnutrition in hemodialysis patients is frequent and it is associated with a reduction in muscular mass, strength, functional capacity and quality of life, with an increment in inflammatory and oxidative markers, and with a dysregulation of circulating miRNAs and its target genes. Animal and human studies have reported that some dietary components (macronutrients, micronutrients and other bioactive substances) might restore these altered features. Thus, we hypothesized that the intake of an oral nutritional supplement (ONS) specifically developed for malnourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine, and with or without probiotics) vs. individualized diet recommendations might: Improve nutritional status (visceral proteins, muscular mass), functional capacity and quality of life. Reduce inflammatory and oxidative markers, and modulate the circulating levels of some miRNAs and the expression of its target genes on cells. miRNAs may be useful biomarkers to check the response to a nutritional intervention in malnourished hemodialysis patients. The present study is a randomized, multicenter, parallel-group trial with 3 groups, open to the intake of ONS or individualized diet recommendations, but double-blind to the intake of probiotics. Inclusion criteria comprised adult subjects (>18 y/o) undergoing hemodialysis more than 6 months previous at inclusion and at least one of these caloric malnutrition criteria: a) involuntary weight loss >5% in 3 months or >10% in 6 months; b) serum albumin < 3.5 g/dl or prealbumin <28 mg/dl; c) body mass index (BMI) < 23 kg/m2; d) muscular mass loss >5% in 3 months or >10% in 6 months. The study duration is 6 months, and comprises 4 visits (screening, basal, 3 months and 6 months). A nutritional examination that included anthropometric measurements, handgrip strength measured by a hand dynamometer, body composition assessed by bioelectrical impedance analysis (BIA) and a 5 days dietary record; quality of life evaluation by the "12-item short form health survey"; the presence of symptoms of depression and anxiety (Hospital Anxiety and Depression Scale); assessment of functional status by the "Barthel" test, the "Short Physical Performance Battery" and the "International Physical Activity Questionnaire"; and blood and stool samples will be obtained for each participant in each study visit (except screening visit).
Detailed Description
Hypothesis: The intake of an oral nutritional supplement (ONS) specifically developed for malnourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine, and with or without probiotics) vs. individualized diet recommendations might: Improve nutritional status (visceral proteins, muscular mass), functional capacity and quality of life. Reduce inflammatory and oxidative markers, and modulate the circulating levels of some miRNAs and the expression of its target genes on cells. miRNAs may be useful biomarkers to check the response to a nutritional intervention in undernourished hemodialysis patients. Aims: To evaluate: The clinical response after the nutritional intervention: Nutritional status: anthropometric measurements, handgrip strength measured by a jamar hand dynamometer, body composition assessed by bioelectrical impedance analysis (BIA), and a 5 days dietary record. Functional status assessed by the "Barthel" test, the "Short Physical Performance Battery" and the "International Physical Activity Questionnaire". Quality of life assessed by the "12-item short form health survey", and the presence of symptoms of depression and anxiety by the "Hospital Anxiety and Depression Scale". The physiological response after the nutritional intervention: Inflammatory markers. Oxidative markers. Gut microbiota. Circulating miRNAs and the expression of its target genes on cells. Study design: Randomized, multicenter, parallel-group trial with 3 groups, open to the intake of ONS or diet, but double-blind to the intake of probiotics. Study centers: Hospital Regional Universitario de Málaga (Spain). Hospital San Cecilio. Granada (Spain). Hospital Rey Juan Carlos. Móstoles, Madrid (Spain). One-hundred and twenty patients will be included. Eligible subjects will be invited to participate, and written informed consent will be obtained before the inclusion. Participants will be randomly assigned to one of these three groups: ONS with probiotics. Dietary and physical activity recommendations. ONS without probiotics. Dietary and physical activity recommendations. Dietary and physical activity recommendations. The study duration is 6 months, and comprises 4 visits (screening, basal, 3 months and 6 months). Recruitment period: 12 months. Inclusion criteria: adult subjects (>18 y/o) undergoing hemodialysis more than 6 months previous at inclusion and at least one of these caloric malnutrition criteria: a) involuntary weight loss >5% in 3 months or >10% in 6 months; b) serum albumin < 3.5 g/dl or prealbumin <28 mg/dl; c) body mass index (BMI) < 23 kg/m2; d) muscular mass loss >5% in 3 months or >10% in 6 months. A nutritional examination that included anthropometric measurements, handgrip strength measured by a jamar hand dynamometer, body composition assessed by bioelectrical impedance analysis (BIA) and a 5 days dietary record; quality of life evaluation by the "12-item short form health survey"; the presence of symptoms of depression and anxiety (Hospital Anxiety and Depression Scale); assessment of functional status by the "Barthel" test, the "Short Physical Performance Battery" and the "International Physical Activity Questionnaire"; and blood and stool samples will be obtained for each participant in each study visit (except screening visit).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malnutrition, End Stage Renal Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, multicenter, parallel-group trial.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Open to the intake of ONS or diet, but double-blind to the intake of probiotics
Allocation
Randomized
Enrollment
54 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oral nutritional supplement with probiotics
Arm Type
Experimental
Arm Description
Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), with probiotics. Physical activity recommendations.
Arm Title
Oral nutritional supplement without probiotics
Arm Type
Experimental
Arm Description
Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants, carnitine), without probiotics. Physical activity recommendations.
Arm Title
Individualized dietary recommendations
Arm Type
Active Comparator
Arm Description
Individualized dietary recommendations. Physical activity recommendations.
Intervention Type
Dietary Supplement
Intervention Name(s)
Oral nutritional supplement with probiotics
Other Intervention Name(s)
Physical activity recommendations.
Intervention Description
Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.
Intervention Type
Dietary Supplement
Intervention Name(s)
Oral nutritional supplement without probiotics
Other Intervention Name(s)
Physical activity recommendations.
Intervention Description
Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.
Intervention Type
Other
Intervention Name(s)
Dietary recommendations
Other Intervention Name(s)
Physical activity recommendations.
Intervention Description
Dietary recommendations
Primary Outcome Measure Information:
Title
Change in weight
Description
Weight in kg
Time Frame
Baseline and 6 months
Title
Change in fat free body mass
Description
Fat free body mass in kg assessed by bioelectrical impedance analysis
Time Frame
Baseline and 6 months
Title
Change in serum albumin concentration
Description
Serum albumin in g/dl
Time Frame
Baseline and 6 months
Title
Change in serum prealbumin concentration
Description
Serum prealbumin in mg/dl
Time Frame
Baseline and 6 months
Secondary Outcome Measure Information:
Title
Change in handgrip strength
Description
Handgrip strength in kg, measured by the jamar hydraulic hand dynamometer.
Time Frame
Baseline and 6 months
Title
Change in the score of the "Barthel" test.
Description
The Barthel is a 10-item ordinal scale that measures functional independence in the domains of personal care and mobility. Specifically, it measures self-care, sphincter management, transfers and locomotion. The score ranges between 0 and 100 points. Scores of 0-20 indicate "total" dependency, 21-60 indicate "severe" dependency, 61-90 indicate "moderate" dependency, 91-99 indicates "slight" dependency, and 100 indicates independency.
Time Frame
Baseline and 6 months
Title
Change in the score of the Hospital Anxiety and Depression Scale (HADS).
Description
Symptoms of depression and anxiety assessed by the Hospital Anxiety and Depression Scale (HADS). This questionnaire comprises two sub-scales, each one range from 0 to 21 points; one assesses the symptoms of depression, and the other one the symptoms of anxiety. At each sub-scale, a score below 7 is considered normal range, between 8 and 10 means probable presence of depression or anxiety respectively, and more than 11 suggests the presence of depression or anxiety respectively.
Time Frame
Baseline and 6 months
Title
Changes in plasma levels of high sensitivity C reactive protein (hs-CRP)
Description
Plasma levels of high sensitivity C reactive protein (hs-CRP) in mg/dl
Time Frame
Baseline and 6 months
Title
Changes in plasma levels of 8-iso-prostaglandina F2 α (8-iso-PGF2-α)
Description
Plasma levels of 8-iso-prostaglandina F2 α (8-iso-PGF2-α) in pg/ml
Time Frame
Baseline and 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult subjects (>18 y/o) undergoing hemodialysis more than 6 months previous at inclusion. At least one of these caloric malnutrition criteria: a) involuntary weight loss >5% in 3 months or >10% in 6 months; b) serum albumin < 3.5 g/dl or prealbumin <28 mg/dl; c) body mass index (BMI) < 23 kg/m2; d) muscular mass loss >5% in 3 months or >10% in 6 months. Standard hemodialysis therapy (3 days/week, 240 min, high permeability dialyzer, blood flow >250 ml/min and dialysate flow 500 ml/min) or on-line hemodialysis therapy that was not modified in the last 3 months previous to the inclusion. Written informed consent obtained. Exclusion Criteria: Type 1 diabetes mellitus or type 2 diabetes mellitus with HbA1c>9%. Unstable dry weight. Limb amputation. Significant edema. Active malignancy. Hospital admissions in the last 3 months. Acute gastrointestinal disease in the 2 weeks before the inclusion. Gastrectomy, gastroparesis or abnormal gastric emptying. Acute heart failure grade IV. Severe hepatic insufficiency (men gamma glutamyl transferase -GGT- >150 U/l, women >120 U/l). Alcohol or other drugs abuse. Participants enrolled in other research study at inclusion. Pregnant women. No informed consent obtained. Patients who received any oral nutritional supplement (specific for hemodialysis patients or not) in the 4 weeks before the inclusion. Patients receiving enteral tube feeding. Galactosemia, fructosemia, or requirement of a no fiber diet. Allergy or hypersensitivity to any ingredient of the oral nutritional supplement. Ongoing treatment with glucocorticoids. Patients who received any oral fatty acids omega-3 supplement in the 4 weeks before the inclusion. Patients who received intradialytic parenteral nutrition in the 3 months before the inclusion. Patients who received any probiotics or prebiotics (not as part of the diet) in the 3 months before the inclusion. Anemia (Hemoglobin < 10 g/dl) or Epoetin resistance.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gabriel Olveira, MD, PhD
Organizational Affiliation
Instituto de Investigación biomédica de Málaga
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitario Rey Juan Carlos
City
Móstoles
State/Province
Madrid
Country
Spain
Facility Name
Hospital San Cecilio
City
Granada
Country
Spain
Facility Name
Hospital Regional Universitario de Málaga
City
Málaga
ZIP/Postal Code
29009
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
The data will be published when the trial will be finished.

Learn more about this trial

Oral Nutritional Supplement on Nutritional and Functional Status, and Biomarkers in Malnourished Hemodialysis Patients.

We'll reach out to this number within 24 hrs